Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ALNY

Alnylam Pharmaceuticals Inc

May 07 • 04:00PM ET

154.33

Dollar change +3.11
Percentage change 2.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VO VXF VUG IBB VOT IWP VHT IWR IWF

Index	-	P/E	-	EPS (ttm)	-2.68	Insider Own	0.54%	Shs Outstand	126.49M	Perf Week	7.21%
Market Cap	19.52B	Forward P/E	-	EPS next Y	-1.95	Insider Trans	-10.11%	Shs Float	125.80M	Perf Month	-1.10%
Income	-332.08M	PEG	-	EPS next Q	-1.06	Inst Own	93.06%	Short Float	1.99%	Perf Quarter	-10.37%
Sales	2.00B	P/S	9.74	EPS this Y	-2.58%	Inst Trans	0.95%	Short Ratio	3.07	Perf Half Y	-7.78%
Book/sh	-1.73	P/B	-	EPS next Y	46.08%	ROA	-9.20%	Short Interest	2.50M	Perf Year	-24.86%
Cash/sh	18.75	P/C	8.23	EPS next 5Y	-	ROE	-1500.66%	52W Range	141.98 - 218.88	Perf YTD	-19.37%
Dividend Est.	-	P/FCF	152.72	EPS past 5Y	14.18%	ROI	-13.97%	52W High	-29.49%	Beta	0.30
Dividend TTM	-	Quick Ratio	3.07	Sales past 5Y	97.61%	Gross Margin	83.95%	52W Low	8.70%	ATR (14)	4.41
Dividend Ex-Date	-	Current Ratio	3.17	EPS Y/Y TTM	69.50%	Oper. Margin	-8.78%	RSI (14)	59.89	Volatility	3.48% 2.74%
Employees	2100	Debt/Eq	-	Sales Y/Y TTM	75.20%	Profit Margin	-16.58%	Recom	1.80	Target Price	218.58
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	62.74%	Payout	-	Rel Volume	0.43	Prev Close	151.22
Sales Surprise	15.50%	EPS Surprise	53.41%	Sales Q/Q	54.82%	Earnings	May 02 BMO	Avg Volume	813.62K	Price	154.33
SMA20	4.42%	SMA50	3.10%	SMA200	-9.79%	Trades		Volume	353,436	Change	2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$181 → $208
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$144 → $225
Nov-22-21	Upgrade	Goldman	Neutral → Buy	$273

Show Previous Ratings

Today 09:12AM	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating (MT Newswires)
08:00AM	Alnylam Issues 2023 Corporate Responsibility Report (Business Wire)
May-03-24 01:01PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:29PM	Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y (Zacks)
10:48AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
03:11AM	Loading…
03:11AM	Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
01:06AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
May-02-24 12:53PM	ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:00AM	Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:04AM	Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed (MT Newswires)
08:08AM	Alnylam: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
May-01-24 08:10AM	Pfizers strong Vyndaqel sales draw attention to rare disease drugs patent life (BioPharma Dive)
Apr-30-24 09:15AM	Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
07:00AM	Loading…
07:00AM	Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia (PR Newswire)
Apr-29-24 09:49AM	5 Most Promising Stocks to Buy Before They Take Off (Insider Monkey)
Apr-25-24 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-18-24 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results (Business Wire)
Apr-08-24 08:44AM	Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick (Zacks)
Apr-07-24 08:00AM	Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension (Business Wire)
Mar-20-24 08:00AM	Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session (Business Wire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-13-24 07:30AM	Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease (Business Wire)
Mar-06-24 11:26AM	Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal (Zacks)
Mar-05-24 09:06AM	ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category (PR Newswire)
08:27AM	Roche, Alnylam say blood pressure drug succeeds in mid-stage trial (Reuters)
07:52AM	Alnylam, Roche blood pressure drug scores in second mid-stage trial (BioPharma Dive)
07:30AM	Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives (Business Wire)
Feb-27-24 08:30AM	Alnylam to Webcast Presentations at Upcoming March Investor Conferences (Business Wire)
08:45AM	Loading…
Feb-24-24 08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-21-24 12:06PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-16-24 12:08PM	Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10% (Zacks)
09:46AM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:55AM	Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
12:02AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 12:39PM	Why Alnylam Pharmaceuticals Stock Is Sinking Today (Motley Fool) -10.19%
10:30AM	Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:37AM	Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ... (GuruFocus.com)
08:17AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
06:54AM	Alnylam changes to heart drug trial spark doubts, sinking shares (BioPharma Dive)
Feb-13-24 07:48PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-12-24 09:16AM	Gear Up for Alnylam (ALNY) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Feb-08-24 10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-05-24 05:02PM	Insider Sell: EVP, CLO & Secretary Indrani Franchini Sells 1,591 Shares of Alnylam ... (GuruFocus.com)
Jan-30-24 03:02PM	Baillie Gifford Adjusts Stake in Alnylam Pharmaceuticals (GuruFocus.com)
Jan-29-24 08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Jan-09-24 08:05AM	Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomens Association (Business Wire)
Jan-08-24 01:49PM	Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues (Zacks)
Jan-07-24 06:00PM	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates (Business Wire)
Jan-02-24 07:30AM	Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-23 02:07AM	Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug (BioPharma Dive) +5.45%
Dec-19-23 11:41AM	13 Most Promising Healthcare Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:30AM	Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day (Business Wire)
Dec-07-23 07:53PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Dec-06-23 08:00AM	Alnylam to Webcast Virtual R&D Day (Business Wire)
Nov-30-23 08:00AM	Alnylam Ranks #1 on Boston Globes Top Places to Work List for 2023 (Business Wire)
Nov-11-23 04:00PM	Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk (Business Wire)
Nov-09-23 09:25AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Nov-08-23 09:55AM	Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a Bet (Zacks)
Nov-07-23 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-04-23 01:08PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 11:47AM	Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues (Zacks)
11:06AM	Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales (Zacks)
Nov-02-23 10:09AM	Alnylam Pharmaceuticals Inc (ALNY) Reports 35% YoY Growth in Q3 2023 Net Product Revenues (GuruFocus.com)
10:00AM	Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:12AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
Oct-26-23 02:00PM	Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year (Business Wire)
10:02AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)
Oct-25-23 05:19PM	Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine (Business Wire)
11:05AM	Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
Oct-19-23 07:28PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results (Business Wire)
Oct-12-23 08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-10-23 10:24AM	Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro (Zacks)
Oct-09-23 04:35PM	Tesla, Bristol Myers-Mirati deal, Alnylam Pharma: Top Tickers (Yahoo Finance Video)
04:08PM	Alnylam Is Now 'One Of The Most Binary' Stories In Biotech. Why The FDA Rejected Its Heart Drug. (Investor's Business Daily)
10:34AM	Alnylam Stock Is Dropping on Surprising FDA Rejection (Barrons.com)
10:19AM	Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug (Investor's Business Daily)
07:49AM	UPDATE 2-Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval (Reuters)
07:36AM	US FDA declines to approve expanded use of Alnylam's heart-disease drug (Reuters)
07:30AM	Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
Oct-08-23 06:29AM	2 Growth Stocks That Could Rocket Higher Before the End of 2023 (Motley Fool)
Oct-06-23 07:00AM	Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023 (Business Wire)
Sep-20-23 12:12PM	13 Best Beaten Down Stocks To Buy Now (Insider Monkey)
Sep-14-23 04:07PM	Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer (Investor's Business Daily) -8.78%
09:36AM	Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod (Zacks)
Sep-13-23 06:24PM	U.S. FDA panel backs expanded use of Alnylam's gene silencing drug (Reuters)
04:57PM	Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
08:08AM	Buy List Alert: 3 Pharma Stocks with Positive Trial Updates (InvestorPlace)
07:00AM	Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
Sep-08-23 09:58AM	Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More (Zacks)
06:52AM	Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study (Zacks)
Sep-07-23 11:30AM	Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report? (Zacks)
07:22AM	UPDATE 2-Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial (Reuters)
07:08AM	Alnylam hypertension drug meets main goal in mid-stage study (Reuters)
07:00AM	Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk (Business Wire)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHARP PHILLIP A	Director	Feb 29 '24	Option Exercise	59.25	30,000	1,777,500	30,000	Mar 01 04:12 PM
SHARP PHILLIP A	Director	Feb 29 '24	Sale	151.34	30,000	4,540,071	0	Mar 01 04:12 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '24	Sale	155.31	2,932	455,357	48,128	Feb 29 04:18 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '24	Sale	155.30	574	89,145	8,666	Feb 29 04:17 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '24	Sale	155.30	574	89,145	19,478	Feb 29 04:18 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '24	Sale	155.30	501	77,805	5,236	Feb 29 04:18 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 28 '24	Sale	155.30	329	51,094	4,133	Feb 29 04:16 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 27 '24	Option Exercise	0.00	878	0	4,462	Feb 29 04:16 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '24	Option Exercise	0.00	5,921	0	51,060	Feb 29 04:18 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '24	Option Exercise	0.00	1,667	0	5,737	Feb 29 04:18 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '24	Option Exercise	0.00	1,908	0	20,052	Feb 29 04:18 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '24	Option Exercise	0.00	1,908	0	9,240	Feb 29 04:17 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 16 '24	Sale	148.06	7,030	1,040,885	45,139	Feb 20 04:07 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 16 '24	Sale	148.06	1,308	193,666	7,332	Feb 20 04:09 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 16 '24	Sale	148.06	1,009	149,397	4,070	Feb 20 04:08 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 16 '24	Sale	148.06	1,007	149,099	18,144	Feb 20 04:08 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 02 '24	Sale	170.99	1,591	272,050	3,584	Feb 05 04:05 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 01 '24	Option Exercise	0.00	5,175	0	5,175	Feb 05 04:05 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Option Exercise	96.45	30,000	2,893,500	46,029	Dec 29 04:03 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Sale	195.00	30,000	5,850,000	16,029	Dec 29 04:03 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Aug 07 '23	Sale	183.89	4,166	766,083	4,345	Aug 07 06:05 PM
Vaishnaw Akshay	President	Aug 04 '23	Sale	185.85	4,057	753,986	22,774	Aug 07 06:04 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 04 '23	Sale	185.85	4,057	753,986	35,216	Aug 07 06:04 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Aug 04 '23	Sale	185.85	3,461	643,223	8,511	Aug 07 06:05 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 04 '23	Sale	185.85	3,460	643,037	15,873	Aug 07 06:05 PM
BONNEY MICHAEL W	Director	Aug 03 '23	Sale	185.38	6,448	1,195,310	16,029	Aug 04 04:02 PM
BONNEY MICHAEL W	Director	Aug 02 '23	Option Exercise	0.00	22,477	0	22,477	Aug 04 04:02 PM

Open in Screener

ASR

Grupo Aeroportuario Del Sureste S.A. ADR

May 07 • 04:00PM ET

336.60

Dollar change -7.66
Percentage change -2.23	%

Industrials • Airports & Air Services • Mexico • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ASR Grupo Aeroportuario Del Sureste S.A. ADR daily Stock Chart

Index	-	P/E	16.21	EPS (ttm)	20.76	Insider Own	0.41%	Shs Outstand	27.70M	Perf Week	-2.29%
Market Cap	9.32B	Forward P/E	12.70	EPS next Y	26.50	Insider Trans	0.00%	Shs Float	27.59M	Perf Month	1.88%
Income	622.82M	PEG	-	EPS next Q	5.79	Inst Own	11.21%	Short Float	0.48%	Perf Quarter	7.58%
Sales	1.55B	P/S	6.02	EPS this Y	17.60%	Inst Trans	-7.17%	Short Ratio	2.97	Perf Half Y	51.65%
Book/sh	95.73	P/B	3.52	EPS next Y	11.88%	ROA	14.94%	Short Interest	0.13M	Perf Year	22.27%
Cash/sh	36.54	P/C	9.21	EPS next 5Y	-0.10%	ROE	23.61%	52W Range	161.01 - 357.90	Perf YTD	14.38%
Dividend Est.	14.60 (4.34%)	P/FCF	13.57	EPS past 5Y	17.28%	ROI	17.74%	52W High	-5.95%	Beta	1.15
Dividend TTM	-	Quick Ratio	4.52	Sales past 5Y	17.11%	Gross Margin	60.18%	52W Low	109.06%	ATR (14)	9.57
Dividend Ex-Date	Nov 27, 2023	Current Ratio	4.54	EPS Y/Y TTM	19.02%	Oper. Margin	58.98%	RSI (14)	55.00	Volatility	2.64% 2.91%
Employees	-	Debt/Eq	0.25	Sales Y/Y TTM	15.46%	Profit Margin	40.22%	Recom	1.94	Target Price	346.53
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	34.69%	Payout	-	Rel Volume	0.80	Prev Close	344.26
Sales Surprise	4.21%	EPS Surprise	5.90%	Sales Q/Q	26.57%	Earnings	Apr 22 AMC	Avg Volume	44.12K	Price	336.60
SMA20	2.10%	SMA50	6.87%	SMA200	24.20%	Trades		Volume	35,423	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-14-23	Upgrade	BofA Securities	Underperform → Buy
Nov-28-23	Downgrade	Citigroup	Neutral → Sell	$228 → $222
Oct-24-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-11-23	Downgrade	Goldman	Neutral → Sell	$28
May-22-23	Upgrade	Barclays	Underweight → Overweight
Mar-30-23	Downgrade	JP Morgan	Overweight → Neutral	$520 → $595
Aug-08-22	Upgrade	JP Morgan	Neutral → Overweight
Dec-01-21	Upgrade	Goldman	Sell → Neutral	$179 → $225
Jun-15-21	Upgrade	Scotiabank	Sector Underperform → Sector Perform	$204
Apr-12-21	Downgrade	Goldman	Neutral → Sell	$135 → $165
Mar-11-21	Downgrade	UBS	Buy → Neutral
Oct-06-20	Downgrade	Citigroup	Buy → Neutral
Oct-01-20	Downgrade	Goldman	Buy → Neutral
Sep-14-20	Upgrade	Scotiabank	Sector Underperform → Sector Perform
Apr-16-20	Upgrade	HSBC Securities	Reduce → Hold
Apr-08-20	Upgrade	UBS	Neutral → Buy
Mar-30-20	Upgrade	Citigroup	Sell → Buy
Mar-04-20	Upgrade	BofA/Merrill	Neutral → Buy
Feb-07-20	Downgrade	Morgan Stanley	Equal-Weight → Underweight

Show Previous Ratings

May-06-24 04:30PM	ASUR Announces Total Passenger Traffic for April 2024 (PR Newswire)
Apr-30-24 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Outperforming Other Transportation Stocks This Year? (Zacks)
Apr-24-24 01:21PM	ASUR Announces Resolutions Approved at the General Annual Ordinary Shareholders' Meeting held on April 24th, 2024 (PR Newswire)
10:49AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-22-24 05:15PM	Grupo Aeroportuario del Sureste Q1 EPS, Revenue Increase (MT Newswires)
04:51PM	Loading…
04:51PM	Grupo Aeroportuario del Sureste: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR Reports 1Q24 Financial Results (PR Newswire)
Apr-15-24 05:00PM	ASUR Files Form 20-F 2023 with the U.S. Securities and Exchange Commissionand Publishes Sustainability Report 2023 (PR Newswire)
Apr-12-24 03:00PM	Wall Street Favorites: 3 Travel Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-08-24 04:30PM	ASUR Announces Total Passenger Traffic for March 2024 (PR Newswire)
Mar-07-24 04:30PM	ASUR Calls for a Shareholders' Meeting (PR Newswire)
Mar-06-24 04:30PM	ASUR Announces Total Passenger Traffic for February 2024 (PR Newswire)
Feb-29-24 08:10AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-26-24 07:51PM	Grupo Aeroportuario del Sureste: Q4 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR Reports 4Q23 Financial Results (PR Newswire)
09:40AM	Loading…
Feb-14-24 09:40AM	Has Grupo Aeroportuario del Sureste (ASR) Outpaced Other Transportation Stocks This Year? (Zacks)
Feb-06-24 04:30PM	ASUR Announces Total Passenger Traffic for January 2024 (PR Newswire)
Jan-04-24 04:30PM	ASUR Announces Total Passenger Traffic for December 2023 (PR Newswire)
Dec-13-23 04:30PM	ASUR Announces Approval of its 2024-2028 Investment Plan Totaling Ps.28.5 billion Expressed in Currency as of December 2022 (PR Newswire)
Dec-06-23 04:30PM	ASUR Announces Total Passenger Traffic for November 2023 (PR Newswire)
Nov-06-23 04:30PM	ASUR Announces Total Passenger Traffic for October 2023 (PR Newswire)
Oct-25-23 11:15AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-23-23 05:51PM	Grupo Aeroportuario del Sureste: Q3 Earnings Snapshot (Associated Press Finance)
05:30PM	ASUR Reports 3Q23 Financial Results (PR Newswire)
Oct-19-23 05:20PM	ASUR ANNOUNCES UPDATES ON GOVERNMENT ACTION TO AMEND THE TARIFF BASE REGULATION (PR Newswire)
Oct-18-23 11:48AM	12 Most Undervalued Dividend Stocks To Buy According To Analysts (Insider Monkey)
Oct-10-23 12:10PM	Unveiling the Investment Potential of Grupo Aeroportuario del Sureste SAB de CV (ASR): A Deep ... (GuruFocus.com) +7.30%
Oct-06-23 11:40AM	ASR or DSDVY: Which Is the Better Value Stock Right Now? (Zacks) +5.91%
Oct-05-23 07:43PM	Why Mexican Airport Fees Led to a Stock Market Selloff: Q&A (Bloomberg) -18.14%
05:30PM	ASUR Announces Total Passenger Traffic for September 2023 (PR Newswire)
04:38PM	Loading…
04:38PM	Mexico Stocks Sink After Government Alters Airport Fees (Bloomberg)
12:06PM	Unveiling the Investment Potential of Grupo Aeroportuario del Sureste SAB de CV (ASR): A ... (GuruFocus.com)
11:41AM	Unveiling Grupo Aeroportuario del Sureste SAB de CV (ASR)'s Value: Is It Really Priced Right? A ... (GuruFocus.com)
Oct-04-23 08:10PM	ASUR ANNOUNCES GOVERNMENT ACTION TO CHANGE TARIFF BASE REGULATION (PR Newswire)
Sep-30-23 07:31PM	Is Grupo Aeroportuario del Sureste SAB de CV (ASR) Too Good to Be True? A Comprehensive ... (GuruFocus.com)
Sep-05-23 05:30PM	ASUR Announces Total Passenger Traffic for August 2023 (PR Newswire)
Aug-07-23 05:30PM	ASUR Announces Total Passenger Traffic for July 2023 (PR Newswire)
Jul-24-23 05:41PM	Grupo Aeroportuario del Sureste: Q2 Earnings Snapshot (AP Finance)
05:30PM	ASUR Reports 2Q23 Financial Results (PR Newswire)
Jul-05-23 05:30PM	ASUR Announces Total Passenger Traffic for June 2023 (PR Newswire)
Jun-13-23 09:40AM	Has Allegiant (ALGT) Outpaced Other Transportation Stocks This Year? (Zacks)
Jun-06-23 05:30PM	ASUR Announces Total Passenger Traffic for May 2023 (PR Newswire)
May-08-23 05:30PM	ASUR Announces Total Passenger Traffic for April 2023 (PR Newswire)
Apr-26-23 01:30PM	ASUR Announces Resolutions Approved at the General Annual Ordinary Shareholders' Meeting held on April 26th, 2023 (PR Newswire)
Apr-24-23 05:39PM	Grupo Aeroportuario del Sureste: Q1 Earnings Snapshot (AP Finance)
05:30PM	ASUR Reports 1Q23 Financial Results (PR Newswire)
Apr-20-23 06:28AM	New Strong Sell Stocks for April 20th (Zacks)
Apr-17-23 03:13PM	ASUR Files Form 20-F with the U.S. Securities and Exchange Commission (PR Newswire)
Apr-05-23 04:30PM	ASUR Announces Total Passenger Traffic for March 2023 (PR Newswire)
Apr-03-23 11:40AM	ASR vs. OMAB: Which Stock Is the Better Value Option? (Zacks)
Mar-09-23 04:30PM	ASUR Calls for a Shareholders' Meeting (PR Newswire)
Feb-23-23 04:30PM	ASUR Reports 4Q22 Financial Results (PR Newswire)
Feb-07-23 04:30PM	ASUR Announces Total Passenger Traffic for January 2023 (PR Newswire)
Jan-19-23 12:00PM	Grupo Aeroportuario del Sureste (ASR) Upgraded to Strong Buy: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for January 19th (Zacks)
03:22AM	Best Income Stocks to Buy for January 19th (Zacks)
Jan-17-23 04:59AM	Best Income Stocks to Buy for January 17th (Zacks)
Jan-13-23 10:00AM	Best Momentum Stock to Buy for January 13th (Zacks)
Jan-10-23 10:00AM	Best Momentum Stock to Buy for January 10th (Zacks)
Jan-05-23 04:30PM	ASUR Announces Total Passenger Traffic for December 2022 (PR Newswire)
Jan-02-23 09:40AM	Are Transportation Stocks Lagging Grupo Aeroportuario del Sureste (ASR) This Year? (Zacks)
Dec-15-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Stock Outpacing Its Transportation Peers This Year? (Zacks)
Dec-09-22 09:31AM	Best Income Stocks to Buy for December 9th (Zacks)
Dec-06-22 10:00AM	Best Momentum Stock to Buy for December 6th (Zacks)
Dec-05-22 04:30PM	ASUR Announces Total Passenger Traffic for November 2022 (PR Newswire)
Nov-29-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Outperforming Other Transportation Stocks This Year? (Zacks)
Nov-25-22 08:41AM	New Strong Buy Stocks for November 25th (Zacks)
04:31AM	Best Income Stocks to Buy for November 25th (Zacks)
Nov-11-22 09:40AM	Has Grupo Aeroportuario del Sureste (ASR) Outpaced Other Transportation Stocks This Year? (Zacks)
Nov-07-22 04:30PM	ASUR Announces Total Passenger Traffic for October 2022 (PR Newswire)
Oct-26-22 09:40AM	Are Transportation Stocks Lagging Grupo Aeroportuario del Sureste (ASR) This Year? (Zacks)
Oct-24-22 04:30PM	ASUR Reports 3Q22 Financial Results (PR Newswire)
Oct-10-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Stock Outpacing Its Transportation Peers This Year? (Zacks)
07:56AM	Best Income Stocks to Buy for October 10th (Zacks)
07:17AM	New Strong Buy Stocks for October 10th (Zacks)
Oct-05-22 04:30PM	ASUR Announces Total Passenger Traffic for September 2022 (PR Newswire)
Sep-19-22 11:40AM	DSDVY or ASR: Which Is the Better Value Stock Right Now? (Zacks)
Sep-06-22 04:30PM	ASUR Announces Total Passenger Traffic for August 2022 (PR Newswire)
Aug-04-22 04:30PM	ASUR Announces Total Passenger Traffic for July 2022 (PR Newswire)
Jul-27-22 06:32AM	New Strong Buy Stocks for July 27th (Zacks)
Jul-25-22 04:30PM	ASUR Reports 2Q22 Financial Results (PR Newswire)
Jul-15-22 11:40AM	SNDR vs. ASR: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-06-22 05:52PM	ASUR Announces Total Passenger Traffic for June 2022 (PR Newswire)
Jun-28-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Outperforming Other Transportation Stocks This Year? (Zacks)
Jun-21-22 12:00PM	Grupo Aeroportuario del Sureste (ASR) Upgraded to Strong Buy: Here's Why (Zacks)
Jun-06-22 04:30PM	ASUR Announces Total Passenger Traffic for May 2022 (PR Newswire)
Jun-03-22 09:40AM	Is Delta Air Lines (DAL) Stock Outpacing Its Transportation Peers This Year? (Zacks)
May-27-22 08:05AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V.'s (NYSE:ASR) Stock Has Shown A Decent Performance: Have Financials A Role To Play? (Simply Wall St.)
May-18-22 09:40AM	Is Delta Air Lines (DAL) Outperforming Other Transportation Stocks This Year? (Zacks)
May-05-22 04:30PM	ASUR Announces Total Passenger Traffic for April 2022 (PR Newswire)
May-02-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Stock Outpacing Its Transportation Peers This Year? (Zacks)
Apr-25-22 04:30PM	ASUR Reports 1Q22 Financial Results (PR Newswire)
Apr-20-22 12:24PM	ASUR Announces Resolutions Approved at the General Annual Ordinary Shareholders' Meeting held on April 20, 2022 (PR Newswire)
Apr-14-22 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Outperforming Other Transportation Stocks This Year? (Zacks)
Apr-08-22 05:46PM	ASUR Files Form 20-F with the U.S. Securities and Exchange Commission (PR Newswire)
Apr-06-22 04:30PM	ASUR Announces Total Passenger Traffic for March 2022 (PR Newswire)
Mar-22-22 09:40AM	Has Grupo Aeroportuario del Sureste (ASR) Outpaced Other Transportation Stocks This Year? (Zacks)
Mar-10-22 04:53PM	ASUR Calls for a Shareholders' Meeting (PR Newswire)
Mar-07-22 04:30PM	ASUR Announces Total Passenger Traffic for February 2022 (PR Newswire) -8.16%
Mar-04-22 08:30AM	Opinion of the Board of Directors on the Price of the Voluntary Public Offering of Aeroméxico's shares launched by a Third Party Offeror (PR Newswire)

Grupo Aeroportuario del Sureste SA de CV is a holding company, which engages in the operation, maintenance, and development of airports It operates through the following segments: Cancun, Aerostar, Airplan, Villahermosa, Merida, Holding and Services, and Other. The company was founded in 1996 and is headquartered in Mexico City, Mexico.

Open in Screener

OMER

Omeros Corporation

May 07 • 04:00PM ET

3.64

Dollar change -0.03
Percentage change -0.82	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

OMER Omeros Corporation daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO IWO FDM IWC SMLF

Index	RUT	P/E	-	EPS (ttm)	-1.88	Insider Own	4.05%	Shs Outstand	61.13M	Perf Week	15.56%
Market Cap	210.90M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	1.08%	Shs Float	55.60M	Perf Month	6.43%
Income	-117.81M	PEG	-	EPS next Q	-0.56	Inst Own	43.26%	Short Float	23.62%	Perf Quarter	8.66%
Sales	0.00M	P/S	-	EPS this Y	-11.17%	Inst Trans	-13.89%	Short Ratio	29.07	Perf Half Y	184.38%
Book/sh	-0.41	P/B	-	EPS next Y	14.21%	ROA	-36.09%	Short Interest	13.13M	Perf Year	-28.91%
Cash/sh	2.97	P/C	1.23	EPS next 5Y	-	ROE	-576.33%	52W Range	0.92 - 7.80	Perf YTD	11.31%
Dividend Est.	-	P/FCF	2.84	EPS past 5Y	6.37%	ROI	-36.49%	52W High	-53.32%	Beta	1.37
Dividend TTM	-	Quick Ratio	4.09	Sales past 5Y	34.87%	Gross Margin	-	52W Low	295.65%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	4.09	EPS Y/Y TTM	-348.50%	Oper. Margin	0.00%	RSI (14)	57.05	Volatility	7.48% 7.04%
Employees	198	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-107.08%	Payout	-	Rel Volume	0.33	Prev Close	3.67
Sales Surprise	-	EPS Surprise	72.97%	Sales Q/Q	-	Earnings	Apr 01 AMC	Avg Volume	451.79K	Price	3.64
SMA20	8.01%	SMA50	-0.49%	SMA200	14.42%	Trades		Volume	147,713	Change	-0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral	$21 → $15
Mar-17-17	Reiterated	Needham	Buy	$24 → $22
Mar-17-17	Reiterated	Maxim Group	Buy	$19 → $22
Nov-16-16	Reiterated	Wedbush	Outperform	$56 → $47

Show Previous Ratings

Apr-02-24 12:41PM	Q4 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 09:53PM	OMER Stock Earnings: Omeros Misses EPS for Q4 2023 (InvestorPlace) -7.54%
05:32PM	Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results (GuruFocus.com)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-27-24 08:30AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 (Business Wire)
Mar-17-24 10:02AM	Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade (InvestorPlace)
Feb-20-24 09:00AM	Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Feb-07-24 09:34AM	3 Sleeper Stocks Under $15 Ready to Explode by 2029 (InvestorPlace)
Feb-01-24 09:11AM	Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-11-23 03:01PM	Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 09:43AM	Q3 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	Omeros Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 08:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 (Business Wire) +6.25%
Nov-03-23 09:05AM	Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Nov-02-23 09:05AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +7.96%
Oct-19-23 08:30AM	Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer (Business Wire) -10.32%
Oct-16-23 08:36AM	Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price (FierceBiotech.com) -32.16%
07:59AM	UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study (Reuters)
07:44AM	Omeros to shut kidney disease trial as therapy fails in late-stage study (Reuters)
07:30AM	Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy (Business Wire)
Aug-09-23 08:08AM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Omeros Corporation Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-04-23 08:00AM	Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023 (Business Wire)
Jun-21-23 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -7.31%
Jun-12-23 02:47PM	Why Shares of Omeros Dropped on Monday (Motley Fool) -14.53%
08:45AM	Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress (Business Wire)
11:00AM	Loading…
Jun-01-23 11:00AM	Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress (Business Wire) +17.42%
May-09-23 04:41PM	Omeros: Q1 Earnings Snapshot (AP Finance)
04:02PM	Omeros Corporation Reports First Quarter 2023 Financial Results (Business Wire)
May-04-23 04:06PM	Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023 (Business Wire)
Apr-25-23 09:25AM	Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (Business Wire) -5.32%
Apr-10-23 08:45AM	Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program (Business Wire) +7.31%
Mar-29-23 09:07AM	Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day (Zacks) +9.42%
Mar-28-23 09:34AM	3 Medical Stocks Creating Wealth Despite Macro Challenges (Zacks)
Mar-14-23 11:11AM	Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript (Insider Monkey) +9.28%
10:06AM	Q4 2022 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-13-23 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results (Business Wire) +5.83%
Mar-10-23 03:37PM	Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank (Business Wire) -10.93%
Mar-07-23 09:00AM	Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023 (Business Wire)
Feb-09-23 02:43PM	Why Omeros Stock Bolted Higher This Week (Motley Fool)
Feb-06-23 11:30AM	Why Omeros Corporation Stock Is Skyrocketing Today (Motley Fool) +61.17%
08:50AM	Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical (Business Wire)
Nov-09-22 04:02PM	Omeros Corporation Reports Third Quarter 2022 Financial Results (Business Wire) -11.88%
Nov-08-22 08:30AM	Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab (Business Wire)
Nov-04-22 09:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022 (Business Wire) -5.03%
Nov-03-22 09:00AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire)
Oct-03-22 07:10AM	Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust (Business Wire) +10.79%
Sep-15-22 10:51AM	Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless (Benzinga) -25.97%
09:06AM	Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial (Business Wire)
09:02AM	I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19 (Business Wire)
Aug-17-22 08:40AM	Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab (Business Wire)
Aug-10-22 05:01PM	Omeros reports growing Omidria sales after deal with British eye care company (American City Business Journals) +20.32%
Aug-09-22 04:02PM	Omeros Corporation Reports Second Quarter 2022 Financial Results (Business Wire) -8.15%
Aug-08-22 11:35AM	How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? (Simply Wall St.)
Aug-04-22 09:55AM	Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High? (Zacks) +6.51%
08:30AM	Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022 (Business Wire)
Jul-29-22 02:48PM	Why Omeros Corporation Stock Is Marching Higher Today (Motley Fool) +11.41%
08:45AM	FDA Grants Orphan Drug Designation to Omeros MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria (Business Wire)
Jul-05-22 05:46PM	Why Omeros Stock Is Freefalling Today (Motley Fool) -33.41%
Jun-15-22 08:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.13%
May-10-22 04:02PM	Omeros Corporation Reports First Quarter 2022 Financial Results (Business Wire)
May-04-22 08:30AM	Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022 (Business Wire) +6.06%
Apr-20-22 08:45AM	Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA (Business Wire) -8.30%
Mar-01-22 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results (Business Wire)
08:59AM	How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? (Simply Wall St.)
Feb-28-22 08:34AM	Why Earnings Season Could Be Great for Omeros (OMER) (Zacks)
Feb-24-22 07:00AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022 (Business Wire) +7.74%
Feb-03-22 09:38AM	Bellevue Asset Management, Llc Buys First Trust Low Duration Mortgage Opportunities ET, eBay ... (GuruFocus.com)
Jan-20-22 06:54AM	Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA (Benzinga)
Jan-19-22 05:52PM	Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA (Business Wire)
Dec-30-21 05:11PM	Omeros receives $126M in sale of drug franchise to British eye care company (American City Business Journals)
Dec-23-21 09:10AM	Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical (Business Wire)
Dec-20-21 09:30AM	OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER (PR Newswire) +5.59%
Dec-15-21 11:34AM	Do Options Traders Know Something About Omeros (OMER) Stock We Don't? (Zacks)
Dec-03-21 08:17PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm (Newsfile) -6.15%
Dec-02-21 08:22PM	Seattle biotech Omeros selling drug franchise in deal valued at over $1B (American City Business Journals) +7.33%
07:30AM	Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion (Business Wire)
05:58AM	Omeros Shares Rally On Agreement to Sell Omidria Cataract Business (Investing.com)
Nov-30-21 07:42AM	Investors in Omeros (NASDAQ:OMER) have unfortunately lost 50% over the last three years (Simply Wall St.)
Nov-09-21 06:25PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Omeros Corporation Reports Third Quarter 2021 Financial Results (Business Wire)
Nov-05-21 04:45PM	Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years (Benzinga)
08:40AM	Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial (Business Wire)
08:30AM	Omeros Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis (Business Wire)
Nov-04-21 10:53AM	Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High? (Zacks)
08:30AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021 (Business Wire)
Nov-01-21 04:35PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm (ACCESSWIRE) +9.73%
03:01PM	Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-31-21 06:19AM	3 Beaten-Down Biotech Stocks -- Can They Recover? (Motley Fool)
Oct-26-21 03:15PM	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm (ACCESSWIRE)
Oct-21-21 10:00AM	Down 59.6% in 4 Weeks, Here's Why Omeros (OMER) Looks Ripe for a Turnaround (Zacks)
Oct-20-21 08:31AM	Omeros (OMER) Soars 9.7%: Is Further Upside Left in the Stock? (Zacks)
Oct-18-21 05:39PM	Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA (Benzinga) -26.65%
12:24PM	Here's Why Omeros Is Sinking Further Today (Motley Fool)
06:30AM	Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA (Business Wire)
Oct-15-21 09:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER (PR Newswire)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Demopulos Gregory A MD	Chairman, CEO & President	Nov 17 '23	Buy	1.68	15,000	25,200	123,945	Nov 21 08:11 PM
Demopulos Peter A MD	Director	Nov 15 '23	Buy	1.53	10,000	15,300	208,516	Nov 17 09:46 PM
Cable Thomas J.	Director	May 22 '23	Option Exercise	5.30	5,000	26,500	40,067	May 23 05:50 PM
HANISH ARNOLD C	Director	May 22 '23	Option Exercise	5.30	5,000	26,500	5,000	May 23 05:53 PM
Cable Thomas J.	Director	May 22 '23	Sale	6.53	5,000	32,650	35,067	May 23 05:50 PM
HANISH ARNOLD C	Director	May 22 '23	Sale	6.46	5,000	32,300	0	May 23 05:53 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ALNY

Alnylam Pharmaceuticals Inc

ASR

Grupo Aeroportuario Del Sureste S.A. ADR

OMER

Omeros Corporation

Upgrade your FINVIZ experience